Guerbet cuts jobs as contrast agent market stagnates
This article was originally published in Clinica
Guerbet is to cut more than a tenth of its workforce in a restructuring programme aimed at improving the French company's position in the shrinking contrast agent market. The measures are expected to cost around Fr80 million ($13.5 million) and will be funded in 1998, which will result in a loss this year. The cuts are expected to result in annual savings of around Fr49 million.
You may also be interested in...
HAL Allergy Group, developer of products for allergy diagnostics and allergen immunotherapy, promoted its principal scientist to chief R&D officer; Starkey Hearing Technologies brought on new health and business development execs to expand its global footprint; and more.
As the coronavirus continues to spread, one of the big four global vaccines companies has committed itself to the fight.